Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  REGENXBIO Inc.    RGNX

REGENXBIO INC.

(RGNX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

REGENXBIO : To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational Highlights

10/28/2020 | 03:06pm EST

ROCKVILLE, Md., Oct. 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Wednesday, November 4, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2020, and recent operational highlights.

To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 4107819. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

 

 

Contacts:

 

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709

Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

Cision
View original content:http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-november-4-to-discuss-third-quarter-2020-financial-results-and-recent-operational-highlights-301162109.html

SOURCE REGENXBIO Inc.


© PRNewswire 2020
All news about REGENXBIO INC.
12/02REGENXBIO : Announces Dosing Of First Patient in Phase I/II Trial of RGX-111 for..
AQ
11/24REGENXBIO : to Present at Upcoming Investor Conferences
AQ
11/23REGENXBIO : to Present at Upcoming Investor Conferences
PR
11/11CLEARSIDE BIOMEDICAL : Announces Third Quarter 2020 Financial Results and Provid..
AQ
11/11REGENXBIO : Announces Presentations at the American Academy of Ophthalmology 202..
AQ
11/05REGENXBIO : to Present at Upcoming Investor Conferences
PR
11/04REGENXBIO : 3Q Earnings Snapshot
AQ
11/04REGENXBIO : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
11/04REGENXBIO INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
10/29REGENXBIO : to Host Conference Call on November 4 to Discuss Third Quarter 2020 ..
AQ
More news